321 related articles for article (PubMed ID: 18753255)
1. FGFR3 and FGFR4 do not mediate renal effects of FGF23.
Liu S; Vierthaler L; Tang W; Zhou J; Quarles LD
J Am Soc Nephrol; 2008 Dec; 19(12):2342-50. PubMed ID: 18753255
[TBL] [Abstract][Full Text] [Related]
2. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
Li H; Martin A; David V; Quarles LD
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
[TBL] [Abstract][Full Text] [Related]
3. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.
Gattineni J; Alphonse P; Zhang Q; Mathews N; Bates CM; Baum M
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F351-8. PubMed ID: 24259513
[TBL] [Abstract][Full Text] [Related]
4. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
Gattineni J; Bates C; Twombley K; Dwarakanath V; Robinson ML; Goetz R; Mohammadi M; Baum M
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F282-91. PubMed ID: 19515808
[TBL] [Abstract][Full Text] [Related]
5. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4.
Gattineni J; Twombley K; Goetz R; Mohammadi M; Baum M
Am J Physiol Renal Physiol; 2011 Aug; 301(2):F371-7. PubMed ID: 21561999
[TBL] [Abstract][Full Text] [Related]
6. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
Han X; Cai C; Xiao Z; Quarles LD
J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
[TBL] [Abstract][Full Text] [Related]
7. Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport.
Sneddon WB; Ruiz GW; Gallo LI; Xiao K; Zhang Q; Rbaibi Y; Weisz OA; Apodaca GL; Friedman PA
J Biol Chem; 2016 Sep; 291(36):18632-42. PubMed ID: 27432882
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic Actions of FGF23.
Erben RG
Toxicol Pathol; 2017 Oct; 45(7):904-910. PubMed ID: 29096595
[TBL] [Abstract][Full Text] [Related]
9. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
10. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice.
Martins JS; Liu ES; Sneddon WB; Friedman PA; Demay MB
Endocrinology; 2019 Oct; 160(10):2204-2214. PubMed ID: 31237611
[TBL] [Abstract][Full Text] [Related]
13. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
Portale AA; Zhang MY; David V; Martin A; Jiao Y; Gu W; Perwad F
PLoS One; 2015; 10(11):e0142924. PubMed ID: 26588476
[TBL] [Abstract][Full Text] [Related]
14. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
15. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
17. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.
Olauson H; Lindberg K; Amin R; Jia T; Wernerson A; Andersson G; Larsson TE
J Am Soc Nephrol; 2012 Oct; 23(10):1641-51. PubMed ID: 22878961
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway.
Delucchi Á; Toro L; Alzamora R; Barrientos V; González M; Andaur R; León P; Villanueva F; Galindo M; Las Heras F; Montecino M; Moena D; Lazcano A; Pinto V; Salas P; Reyes ML; Mericq V; Michea L
J Bone Miner Res; 2019 Oct; 34(10):1851-1861. PubMed ID: 31099911
[TBL] [Abstract][Full Text] [Related]
19. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
